


# Extreem lage frequente elektromagnetische velden effecten op de gezondheid: stand van zaken

Prof. Dr. Luc Verschaeve

Lab. Toxicologie, Wetenschappelijk Instituut Volksgezondheid,  
Brussel & Dpt. Biomedische Wetenschappen, Universiteit  
Antwerpen




## ELF (< 300 kHz)

- Kan men zich aan biologische effecten verwachten?

(< 300V/m et <50µT)

- Niet ioniserend
- Geen verbreking van chemische bindingen
- Geen rechtstreekse DNA schade = geen rechtstreeks genetisch of carcinogen effect
- Veldsterkten/amplitude <<< gekende electrofisiologische mechanismen (vb. afwijkingen t.h.v. de celmembraan)



## ELF (< 300 kHz)

- Kan men zich aan biologische effecten verwachten?

(< 300V/m et <50µT)



**RF radiation:  
biological effects**

Sharp controversy over the effects of electromagnetic radiation  
may subside in the wake of new understanding and modified standards

HOW  
COULD VIDEO  
DISPLAY TERMINALS  
POSSIBLY BE  
LINKED TO  
BIRTH  
DEFECTS?

**Electronic smog fouls the ether**

**Velden op het plan...**  
Ultrasonic teratology in mouse and man\*

**HOOGSPANNINGSLIJNEN  
EN GEZONDHEID**


**Acute Leukaemia in Workers Exposed to  
Electromagnetic Fields**

Sylvie Bastuji-Garin, Sylvia Richardson and Robert Zitterman

Results from a French case-control study of acute leukaemia and occupational exposures to the risk associated with exposure to electromagnetic fields (EMF) are reported. There were 385 cases and 513 controls. A significantly increased risk of acute leukaemia was observed for exposure to EMF other than that from arc welding rods (odds ratio = 4.84, 95% CI 1.26-12.80) which permitted other adjustments for possible confounding exposures. This study supports the hypothesis that workers exposed to some EMF have an increased risk of leukaemia.  
*Eur J Clin Oncol*, Vol. 26, No. 10-12, pp. 1119-1123, 1990.

**Des soupçons planent  
sur les lignes électriques**

Conclusions en demi-teinte après une étude américaine menée  
dans 50 000 employés exposés à des champs électromagnétiques  
que, selon les conclusions de


**POWERLINES**

**Powerline cancers  
to focussing of sol  
by line fields in 11**


IN November 1992 Electronics World journal reported that of the research it had carried out since the previous 18 months into the relation between powerlines and cancer rates, the results suggested that the link between so-called radiation cancers and powerlines noted since the mid-70s might be best explained by a little-known and unexpected focusing effect of penetrating secondary particles created from atmospheric collisions (Bremstrahlung) by powerline electrons and electromagnetic fields.

Independent group addressing hypothesis in attempted replication of unexpected results, of near its home in Upstate New York, indicating powerline fields may focusing secondary particles from atmospheric collisions to powerlines. The other trial has been

accounts for all percent increase in radiation exposure. It will be difficult to prove.



Professor Ivan BEALE of the Auckland University has linked high tension power lines... already associated with higher rates of leukaemia among children...to **asthma** and **depression** in adults. People living within a 20m shadow of high voltage lines are three times as likely to suffer from asthma and twice as likely to have major depression. Researchers believe the danger levels drop rapidly outside the 20m zone. The study also indicates that people have a higher incidence of **diabetes** and are twice as likely to suffer from immune related illnesses such as **allergies**




### STATE OF THE ART: veel beweringen, weinig zekerheden:

De studie van de biologische effecten van elektromagnetische stralen is een gecompliceerd en zeer breed onderzoeksgebied dat een pluridisciplinaire benadering vereist. Deze complexiteit kan de zeer langzame evolutie van onze kennis ter zake en de persistentie van vele onbekenden verklaren.

1. Verschillende types biologische onderzoeken hebben ieder hun specificiteit, voor- en nadelen

*In vitro – in vivo – humaan experimenteel – epidemiologisch*



- A single study can form the basis of an hypothesis, but does not provide the basis for hazard identification.
- Confirmation of the results of any study are needed through replication and/or supportive studies.
- The resulting body of evidence forms the basis for science-based judgments by defining exposure levels for
  - adverse health effects and
  - no observable adverse effects.



## 2. Verschillen in biologisch 'substraat'.

Resultaten kunnen afhangen van het type weefsel dat bestudeerd wordt; bv. de elektrische en magnetische eigenschappen van de weefsels kunnen van het ene weefsel tot het andere verschillen (elektrische geleidbaarheid, permeabiliteit, e.d.), de oriëntatie van het organisme t.o.v. de velden kan ook belangrijk zijn, in sommige gevallen de grootte van het organisme e.d.

## 3. Verschillen in geassocieerde factoren

Biochemische factoren, zoals de aan- of afwezigheid van een chemische stof of pollutant in het lichaam/de cellen (medicatie, verontreinigende stof) of een fysiologische alteratie (eventueel ziekte) kunnen de gevoeligheid aan de velden beïnvloeden. In sommige gevallen werden geen effecten vastgesteld in normale gezonde cellen of organismen maar wel in cellen die op een of andere manier 'uit evenwicht' waren (geïnfecteerd, in herstel of genezing, ...).

4. het type blootstelling kan bepalend zijn:

Continue of chronische blootstelling, partiële of totale lichaamsblootstelling, interferenties met andere blootstellingen zijn ook factoren die een eventueel verschil in biologische respons kunnen verklaren.

5. De complexiteit van een wetenschappelijke benadering

Normaal zal een wetenschapper proberen een oorzakelijk verband vast te stellen (blootstelling aan een bepaald magnetisch veld induceert leukemie bv.) maar omdat van alle mogelijke variabelen die een rol kunnen spelen zal een wetenschapper proberen van een vereenvoudiging in zijn experimenteel werk door te voeren waardoor het aantal parameters die een invloed kunnen hebben op het resultaat beperkt worden. Daarom ook zijn *in vitro* studies belangrijk (men houdt het ‘biologisch systeem’ beter in de hand). Maar dat is dus de realiteit niet meer en het bekomen resultaat is daarom altijd slechts partieel, suggestief, maar niet helemaal zeker.

Daarom zijn resultaten van verschillende studies, die in verschillende laboratoria (en soms zelfs in hetzelfde laboratorium) werden uitgevoerd vaak verschillend. Een verschillende benadering kan leiden tot andere parameters die belangrijk zijn en dus tot een andere uitkomst.

## MAGNETISCHE VELDEN EN LEUKEMIE BIJ KINDEREN



Am J Epidemiol. 1979 Mar;109(3):273-84.  
Electrical wiring configurations and childhood cancer.



Wertheimer N, Leeper E.

An excess of electrical wiring configurations suggestive of high current-flow was noted in Colorado in 1976--1977 near the homes of children who developed cancer, as compared to the homes of control children.

The finding was strongest for children who had spent their entire lives at the same address, and it appeared to be dose-related. It did not seem to be an artifact of neighborhood, street congestion, social class, or family structure. The reason for the correlation is uncertain; possible effects of current in the water pipes or of AC magnetic fields are suggested.

### Epi-studies: beperkingen

- controversiële resultaten
- klein aantal individuen – statistische beperkingen
- vaak “niet blinde” evaluatie (blootstelling, enz.)
- moeilijkheden om directe metingen uit te voeren;  
Waar? Voor welke tijdsduur?
- tegenstrijdigheid tussen gemeten velden en de “wire code” in populatiestudies
- vele vergelijkingen; positieve resultaten worden vaak overgeinterpretieerd
  - “confounders”
- tegenstrijdigheden tussen positieve resultaten
- onbekend werkingsmechanisme



## ELF-MF AND CHILDHOOD LEUKAEMIA

$> 0.4 \mu\text{T}$

IARC



Geen andere overtuigende gegevens inzake effecten op de gezondheid.

Geen aanwijzingen voor gezondheidseffecten in de beroepsbevolking.

Geen aanwijzingen van schadelijke effecten op de gezondheid voor statische velden (tenzij bij zeer hoge blootstelling).



Epidemiology. 2000 Nov;11(6):624-34.

**A pooled analysis of magnetic fields, wire codes, and childhood leukemia. Childhood Leukemia-EMF Study Group.**



[Greenland S](#), [Sheppard AR](#), [Kaune WT](#), [Poole C](#), [Kelsch MA](#).

Br J Cancer. 2000 Sep;83(5):692-8.

**A pooled analysis of magnetic fields and childhood leukaemia.**

[Ahlbom A](#), [Day N](#), [Feychtung M](#), [Roman E](#), [Skinner J](#), [Dockerty J](#), [Linet M](#),  
[McBride M](#), [Michaelis J](#), [Olsen JH](#), [Tynes T](#), [Verkasalo PK](#).

## Experimenteel onderzoek in het laboratorium



Honderden studies kunnen geen uitsluitsel brengen

**British Journal of Cancer (2010) 103, 931–932**  
© 2010 Cancer Research UK. All rights reserved 0007–0920/10



[www.bjancer.com](http://www.bjancer.com)

### Editorial

The association between extremely low-frequency electromagnetic fields and childhood leukaemia in epidemiology: enough is enough?

**S Schmiedel<sup>\*1,2</sup> and M Blettner<sup>1</sup>**

<sup>1</sup>Institute for Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg University Mainz, Mainz 55101, Germany; <sup>2</sup>Danish Cancer Society, Institute for Cancer Epidemiology, Copenhagen 2100, Denmark

**British Journal of Cancer (2010) 103, 931–932. doi:10.1038/sj.bjc.6605837 www.bjancer.com**  
© 2010 Cancer Research UK

# Synoptic Analysis Clarifies Childhood Leukemia Risk from ELF Magnetic Field Exposure

Journal of Electromagnetic Analysis and Applications, 2015, 7, 245-258  
 Published Online October 2015 in SciRes. <http://www.scirp.org/journal/jemaa>  
<http://dx.doi.org/10.4236/jemaa.2015.710026>

Norbert Leitgeb

Institute of Health Care Engineering, Graz University of Technology, Graz, Austria  
 Email: [norbert.leitgeb@tugraz.at](mailto:norbert.leitgeb@tugraz.at)

Received 28 August 2015; accepted 19 October 2015; published 22 October 2015

Copyright © 2015 by author and Scientific Research Publishing Inc.  
 This work is licensed under the Creative Commons Attribution International License (CC BY).  
<http://creativecommons.org/licenses/by/4.0/>



Open Access

## Abstract

In spite of 36 years epidemiologic research, there is still an ongoing controversy about a causal link between childhood leukemia (CL) and exposure to extremely low frequency (ELF) magnetic fields (MF). Public concern has been increased by the fact that ELF MF have been classified as possibly carcinogenic to humans (class 2B) while exposure limits still remain three orders of magnitudes above reported CL risk onset levels. In a new synoptic approach rather than few selected ORs, all reported epidemiological risk estimates (ORs) are analyzed, both pooled together as well as separated into sub-pools of different exposure metric as well as of high and low exposure levels. The results explain the worrying offset of ORs towards increased CL risk as well as the reported puzzling dose-response at low MF levels as an artifact caused by the small-number effect. The synoptic analysis clarifies that ORs critically depend on statistical power. With increasing statistical power ORs decrease and finally converge to and stay at zero risk. This is found consistently at the entire data pool as well as at all sub-pools related to investigated exposure parameters (wave code, distance to MF source, and magnetic field value). Former contradictory results can now be explained. The synoptic analysis provides convincing evidence that the risk of childhood leukemia is not increased by exposure to ELF magnetic fields. IARC's classification of ELF MF needs revision.

## Keywords

Childhood Disease; Epidemiology; ELF Magnetic Fields; Magnetic Field Dose-Response; Synoptic Analysis



**Review Article**

Received: 23 December 2011,

Revised: 28 February 2012,

Accepted: 29 February 2012

Published online in Wiley Online Library

(wileyonlinelibrary.com) DOI 10.1002/jat.2761

# **Health effects of extremely low-frequency magnetic fields: reconsidering the melatonin hypothesis in the light of current data on magnetoreception**

**Jacques Vanderstraeten,<sup>a,\*</sup> Luc Verschaeve,<sup>b,c</sup> Hynek Burda,<sup>d,e</sup>  
Catherine Boulard<sup>a</sup> and Christophe de Brouwer<sup>a</sup>**

**ABSTRACT:** The so-called 'Melatonin Hypothesis' proposed that decreased nocturnal production of melatonin (MLT) might explain the increased risk of breast cancer that has been formerly attributed to extremely low-frequency (ELF) magnetic fields (MF) of weak intensity. Although the risk of ELF MF upon breast cancer was later dismissed, repeated reports were published of partial inhibition of MLT secretion in rats under long-term ( $\geq 4$  weeks) exposure to weak ELF MF. Since 2004, however, this topic has not been experimentally studied any more. In the present study, we propose to go back to the MLT hypothesis and apply it to childhood leukemia, for which an increased risk has been robustly associated with residential exposure to ELF MF. Contrary to the original hypothesis, however, we do not consider decreased MLT levels, but disruption of circadian rhythmicity *per se* as the effector mechanism. Indeed, the role of the circadian timing system in the development of childhood leukemia has been well established. Motivation for going back to the MLT hypothesis comes from recent data that suggest magnetosensory disruption by ELF MF in mammals, and magnetosensitivity in humans, together with current evidence for an influence on circadian rhythmicity from disruption of non-photic sensory stimuli of various natures. We thus suggest further study on circadian rhythmicity in humans (children if possible) under long-term exposure to weak ELF MF.

Copyright © 2012 John Wiley &amp; Sons, Ltd.

Keywords: power-frequency; magnetosensory disruption; circadian biorhythms; nocturnal biorhythms; childhood leukemia

## **Herziening van de melatonine hypothese in het licht van recente gegevens over magnetoreceptie**


### **MELATONINE HYPOTHESE**

- ✓ MLT (krachtige vrije radicaal\* vanger) beschermt tegen (borst)kanker
  - ✓ ELF-MV inhiberen de nachtelijke MLT secretie
  - ✓ ELF-MV effect op de MLT secretie leidt tot een toename in het risico op borstkanker
- Deze hypothese is niet langer weerhouden (geen verdere studies sinds 2004)

**Nu kan met zekerheid gezegd worden dat er GEEN associatie bestaat tussen ELF-MV en borstkanker!**

\*een molecuul of atoom dat één, of meer, ongepaard elektron heeft. Een dergelijke configuratie is energetisch ongunstig en zal makkelijk naar een gepaarde elektronenstructuur overgaan als dit mogelijk is..

## reconsidering the melatonin hypothesis in the light of current data on magnetoreception



25

### ELF-MV: VERSTORING VAN MAGNETORECEPTIE (het waarnemen van magnetische velden) ??

Er zijn aanwijzingen dat een magnetisch veld van  $\geq 0.5 \mu\text{T}$  de magnetoreceptie stimuleert en aldus het circadiaans ritme verstoort.

Die ELF-MV-geïnduceerde verstoring zou leukemie bij kinderen kunnen verklaren.

betere correlatie tussen nachtelijke ELF-MV blootstelling en leukemie bij kinderen  
(t.o.v. 24 uur blootstelling)


#### Epidemiologische gegevens:

Geen risico op kinderleukemie bij  $> 0.3 \mu\text{T}$  (24u) maar wel bij  $> 0.3 \mu\text{T}$  ('s nachts)  
[Wünsch-Filho et al. (2011) Cancer Epidemiol. 35, 534-539].

Invloed van de richting van het ELF-MV en de leeftijd (jonge leeftijd versterkt het effect als gevolg van verschillen in 'circadiaanse fysiologie' tussen jongeren en adulsten); cf. ratexperimenten:

Salti et al. (2000) J. Clin. Endocrinol. Metab. 85, 2137-2144

Rivkees (2003) Pediatr. Endocrinol. Rev. 1, 38-45.



**Int. J. Epidemiol. Advance Access published February 2, 2008**

Published by Oxford University Press on behalf of the International Epidemiological Association  
© The Author 2008; all rights reserved.  
*International Journal of Epidemiology* 2008; 1–12  
doi:10.1093/ije/dym295

## Occupational exposure to extremely low frequency electric and magnetic fields and Alzheimer disease: a meta-analysis

Ana M García,<sup>1,2\*</sup> Antonio Sisternas<sup>1,3</sup> and Santiago Pérez Hoyos<sup>4</sup>

**Accepted** 19 December 2007

**Background** Among potential environmental risk factors for Alzheimer disease (AD), occupational exposures have received some attention, including extremely low frequency electromagnetic fields (ELF-EMF). A systematic review and meta-analysis of published epidemiological studies on this subject was carried out.

**Methods** The search was concluded in April 2006. Bibliographic databases consulted included PubMed, EMBASE, Cochrane Library and NIOSHTIC2. Pooled estimates were obtained using random-effects meta-analysis. Sources of heterogeneity between studies were explored, as was publication bias.

**Results** Fourteen different studies (nine case-control and five cohort studies) accomplished inclusion criteria. All these studies followed standardized criteria for AD diagnosis and most of them obtained quantitative estimates of exposure. Pooled estimates suggest an increased risk of AD from case-control studies ( $OR_{pooled}$  2.03; 95% CI 1.38–3.00) and from cohort studies ( $RR_{pooled}$  1.62; 95% CI 1.16–2.27), with moderate to high statistical heterogeneity in both cases (respectively,  $I^2 = 58\%$  and  $I^2 = 54\%$ ). Cohort studies showed consistently increased risks for exposed men ( $RR_{pooled}$  2.05; 95% CI 1.51–2.80,  $I^2 = 0\%$ ). Evidence of dose-response relationship was not present. Test for publication bias suggests small study effects.

American Journal of Epidemiology Advance Access published November 5, 2008

---

 American Journal of Epidemiology  
© The Author 2008. Published by the Johns Hopkins Bloomberg School of Public Health.  
All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org.

DOI:10.1093/aje/kwn297

---

**Original Contribution**

**Residence Near Power Lines and Mortality From Neurodegenerative Diseases: Longitudinal Study of the Swiss Population**

**Anke Huss, Adrian Spoerri, Matthias Egger, and Martin Röösli for the Swiss National Cohort Study**

*Initially submitted May 5, 2008; accepted for publication August 25, 2008.*

---

The relation between residential magnetic field exposure from power lines and mortality from neurodegenerative conditions was analyzed among 4.7 million persons of the Swiss National Cohort (linking mortality and census data), covering the period 2000–2005. Cox proportional hazard models were used to analyze the relation of living in the proximity of 220–380 kV power lines and the risk of death from neurodegenerative diseases, with adjustment for a range of potential confounders. Overall, the adjusted hazard ratio for Alzheimer's disease in persons living within 50 m of a 220–380 kV power line was 1.24 (95% confidence interval [CI]: 0.80, 1.92) compared with persons who lived at a distance of 600 m or more. There was a dose-response relation with respect to years of residence in the immediate vicinity of power lines and Alzheimer's disease: Persons living at least 5 years within 50 m had an adjusted hazard ratio of 1.51 (95% CI: 0.91, 2.51), increasing to 1.78 (95% CI: 1.07, 2.96) with at least 10 years and to 2.00 (95% CI: 1.21, 3.33) with at least 15 years. The pattern was similar for senile dementia. There was little evidence for an increased risk of amyotrophic lateral sclerosis, Parkinson's disease, or multiple sclerosis.

dementia; neurodegenerative diseases; radiation, nonionizing

---

Abbreviations: ALS, amyotrophic lateral sclerosis; CI, confidence interval; ELF-MF, extremely low frequency magnetic field(s); ICD-10, *International Classification of Diseases, Injuries, and Causes of Death*, Tenth Revision.

Published by Oxford University Press on behalf of the International Epidemiological Association  
© The Author 2008; all rights reserved. Advance Access publication 14 February 2008

*International Journal of Epidemiology* 2008;37:341–343  
doi:10.1093/ije/dyn024

---

## Commentary: Epidemiological research on extremely low frequency magnetic fields and Alzheimer's disease—biased or informative?

Martin Röösli

Accepted 14 January 2008

---

In 2006 the worldwide prevalence of Alzheimer's disease was estimated to be 26.6 million; and by 2050, Alzheimer's disease prevalence is expected to quadruple because of the increasing life expectancy in many countries.<sup>1</sup> Although the years of life lost per Alzheimer's disease case are relatively small, the disease causes considerable distress for afflicted families. Moreover, Alzheimer's disease patients need substantial care resulting in substantial costs for the health care system.

Little is known about the causes of Alzheimer's disease. Several genetic mutations have been identified to be associated with early-onset as well as late-onset disease.<sup>2</sup> In addition, environmental factors are assumed to play an important role, particularly for the development of late-onset Alzheimer's disease.<sup>3</sup> Many environmental, occupational or lifestyle risk factors

assessing long-term exposure to ELF-MF in our everyday environment is complex. There are several occupations where ELF-MF exposure is well characterized and considerably higher than in the everyday environment. It is thus not surprising that all studies on ELF-MF exposure and Alzheimer's disease have focused on occupational exposure and no study has been performed in the general population so far. All epidemiological studies included in the meta-analysis of García *et al.* collected exposure data retrospectively. Collecting retrospective exposure data from Alzheimer's disease patients is particularly problematic if one has to rely on recollection only, being unable to retrieve the information from routine data sources, such as census data or occupation records. In seven of the 14 reviewed epidemiological studies exposure information had to be obtained by

## Review

Received: 18 March 2011,

Revised: 11 July 2011,

Accepted: 11 July 2011

Published online in Wiley Online Library

(wileyonlinelibrary.com) DOI 10.1002/jat.1724

# Can cytogenetics explain the possible association between exposure to extreme low-frequency magnetic fields and Alzheimer's disease?

Annemarie Maes and Luc Verschaeve\*

**ABSTRACT:** Recently, a number of epidemiological studies have suggested that occupational as well as residential exposure to extreme low-frequency electromagnetic fields (ELF-EMFs) may be a risk factor for Alzheimer's disease. This is not proven yet and there are no known biological mechanisms to explain this alleged association. Alzheimer's disease is characterized by a number of events that have, at least partially, a genetic origin. In particular, trisomy of chromosomes 17 and 21 seems to be involved. Overall ELF-EMFs have not been identified as genotoxic agents, but there are some papers in the scientific literature that indicate that they may enhance the effects of agents that are known to induce mutations or tumors. There are also some indications that ELF-EMFs may induce aneuploidy. This opens some perspectives for investigating the alleged association between ELF-EMFs and Alzheimer's. This paper reviews the possibility of a cytogenetic association between the electromagnetic fields and Alzheimer's disease. Copyright © 2011 John Wiley & Sons, Ltd.

**Keywords:** electromagnetic fields; ELF; Alzheimers disease; aneuploidy; genomic instability

31

Matsumoto et al., 22(1), pp. 15–33, 2007  
Advance Access Publication 9 December 2006

REVIEW

A review of genome mutation and Alzheimer's disease

Philip Thomas<sup>1,2,\*</sup> and Michael Fenech<sup>1,2</sup>

<sup>1</sup>CSIRO Health Sciences and Nutrition, PO Box 10001, Adelaide BC,  
Adelaide, South Australia, 5000, Australia; <sup>2</sup>School of Molecular and Biomedical Sciences, The University of New South Wales, NSW 2520, Australia

Alzheimer's disease (AD) is a complex progressive neurodegenerative disorder of the brain and is the commonest form of dementia. The prevalence of this disease is predicted to increase dramatically during the next few decades due to reliable and conclusive diagnostic test exists that will identify individuals presymptomatically or symptomatically. There is a paucity of evidence from dietary and environmental evidence underlying the known pathology of AD and proposes a biologically plausible mechanism that may explain the observed clinical features of the disease. Genome damage biomarkers such as aneuploidy of chromosomes 17 and 21, oxidative damage to DNA and protein shortening associated with overexpression of APP, β amyloid and tau proteins are discussed in terms of their potential value as risk biomarkers. These biomarkers could then be used for diagnosis and the evaluation of potentially effective preventive measures.

### Introduction

Alois Alzheimer (Figure 1) was born in Marktbreit, Germany on June 14, 1864. He studied medicine at the University of Berlin and later at Würzburg where he obtained his doctoral thesis under the supervision of Albert Klemm. After working as a medical resident and then later as a senior physician at the municipal mental asylum in Frankfurt, he developed histopathological stains that allowed the histology of nervous tissue from various neurodegenerative disorders to be assessed.

On November 25, 1901 a patient called Auguste D was admitted to Frankfurt hospital where she was seen and treated by Alois Alzheimer. She had been suffering from the symptoms including paranoia, delusions, hallucinations and impaired memory [1]. After having suffered 5 years of illness, Auguste D died in 1906. Her brain was removed and forwarded onto Alzheimer in Munich, where over the next few months he examined Auguste's brain in great detail. At the Third International Congress of Psychopathology in Paris on November 4, 1906, Alzheimer reported for the first time the histopathological changes that he had witnessed in Auguste's brain. In his journal he wrote: "in the center of an adroit

normal cell there stands out one or several fibres due to their characteristic thickness and peculiar irregularities. They are surrounded by a number of smaller, more uniform fibers. These are determined by the storage of a peculiar substance in the cerebral cortex. All in all we have to face a peculiar disease picture".

The irregular fibers as described by Alzheimer were the neurofibrillary tangles, whereas the smaller fibers were the astrocytic processes and the surrounding glial cells. Both these structures initially described by Alzheimer are now recognized as the characteristic hallmarks of a disease that now bears his name [2].

In 1907 Erich Kretschmer published a chapter in his book, *The Handbook of Psychiatry* where he describes a particularly serious form of senile dementia with early age of onset [3].

Having worked with Kneipelin in Munster from 1903 to 1913, Max Schröder-Kersten became the first professor of Psychiatry in Bremen, Poland. However, with the arrival of the First World War conditions became increasingly more difficult for the patients and the number of dementia cases that had started to fall, Alois Alzheimer died in a dementia coma as a result of rheumatic endocarditis on December 19, 1915, aged 51 years [4]. His work, however, provided the foundation for today's extensive research programme, into trying to understand a disease that is predicted to become a major health burden in the future. As all clinically presented cases being histopathologically confirmed as AD at post mortem [5], worldwide a new case of dementia is predicted to occur every 7 s [6]. The number of dementia cases is estimated to be 24.3 million, with ~4.6 million new cases being diagnosed annually [6]. Currently between 165 000 and 180 000 new cases of dementia are diagnosed each year in Australia [7] and the cost of dementia to the Australian government of \$3.6 billion dollars in lost productivity and medical care [6,7]. These figures are for the developed world and it is predicted that as a greater proportion of an already ageing population reaches retirement age, Alzheimer and the major contributing cause of dementia will increase exponentially [8].

**Clinical diagnosis**

At present, spot criteria of cognitive impairment and behavioural changes patients can be clinically diagnosed with a sensitivity of 80% and specificity of 90% [9].

The symptoms of Alzheimer's disease include memory loss, difficulty performing everyday tasks, confusion, difficulty with language, and changes in mood and behavior. The progression of the disease is gradual and progressive, with memory loss being the earliest symptom. The disease typically begins with mild forgetfulness and gradually progresses to severe memory loss and difficulty performing daily activities. The progression of the disease is gradual and progressive, with memory loss being the earliest symptom. The disease typically begins with mild forgetfulness and gradually progresses to severe memory loss and difficulty performing daily activities. The progression of the disease is gradual and progressive, with memory loss being the earliest symptom. The disease typically begins with mild forgetfulness and gradually progresses to severe memory loss and difficulty performing daily activities.

**Diagnostic tests**

There is no single test that can definitively diagnose Alzheimer's disease. Diagnosis is based on a combination of clinical history, physical examination, cognitive testing, and laboratory tests. These tests can help rule out other causes of cognitive impairment and support the diagnosis of Alzheimer's disease.

**Genetic testing**

Genetic testing can help identify individuals who are at increased risk of developing Alzheimer's disease. The most common genetic risk factor is the APOE ε4 allele, which increases the risk of developing Alzheimer's disease by approximately 4 times.

**Biomarkers**

Biomarkers are substances that can be measured in the blood, cerebrospinal fluid, or brain tissue that are associated with Alzheimer's disease. Biomarkers can help predict the risk of developing Alzheimer's disease and monitor the progression of the disease.

**Imaging**

Imaging techniques such as magnetic resonance imaging (MRI) and positron emission tomography (PET) can help visualize the brain and detect changes associated with Alzheimer's disease.

**Neurofibrillary tangles**

Neurofibrillary tangles are protein filaments that are found in the brains of people with Alzheimer's disease. These tangles are composed of the protein tau and are found in the nerve cells of the brain.

**Abeta**

Abeta is a protein fragment that is found in the brains of people with Alzheimer's disease. Abeta is produced by the breakdown of the protein amyloid precursor protein (APP).

**Tau**

Tau is a protein that is found in the brains of people with Alzheimer's disease. Tau is involved in the formation of neurofibrillary tangles.

**Cholinesterase**

Cholinesterase is an enzyme that is found in the brains of people with Alzheimer's disease. Cholinesterase is involved in the breakdown of acetylcholine, a neurotransmitter that is important for memory and learning.

**Neuroimaging**

Neuroimaging techniques such as MRI and PET can help visualize the brain and detect changes associated with Alzheimer's disease.

**Neurodegeneration**

Neurodegeneration is the process by which nerve cells in the brain die. Alzheimer's disease is a neurodegenerative disorder.

**Neuroinflammation**

Neuroinflammation is the process by which the immune system reacts to damage in the brain. Alzheimer's disease is associated with neuroinflammation.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration and neuroinflammation are closely related processes that are both involved in the progression of Alzheimer's disease.

**Neurodegeneration and neuroinflammation**

Neurodegeneration

## ELF-MV geïnduceerde GENETISCHE EFFECTEN?

- SCENIHR 2015 e.a.:
  - Geen rechtstreekse DNA schade
  - Geen genetische effecten (chromosoombreuken)  
bij < 100 µT
  - Co-mutageen effect ?
  - Genoommutaties?
  - ...

Journal of Alzheimer's Disease 50 (2016) 741–749  
 DOI 10.3233/JAD-150669  
 IOS Press

741

## The Cytome Assay as a Tool to Investigate the Possible Association Between Exposure to Extremely Low Frequency Magnetic Fields and an Increased Risk for Alzheimer's Disease

Annemarie Maes<sup>a</sup>, Roel Anthonissen<sup>a</sup>, Sheleen Wambacq<sup>a,b</sup>, Koen Simons<sup>c</sup> and Luc Verschaeve<sup>a,d,\*</sup>


<sup>a</sup>Scientific Institute of Public Health (WIV-ISP), Toxicology Unit, Brussels, Belgium

<sup>b</sup>Faculty of Pharmacy, Free University of Brussels, Brussels, Belgium

<sup>c</sup>Scientific Institute of Public Health (WIV-ISP), Health and Environment Unit, Brussels, Belgium

<sup>d</sup>Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium

Accepted 2 November 2015



- 1) Toename in frequentie van micronuclei (struct. en/of numerieke chrom. aberr.) en 'bruggen' (struct. chrom. aberr.) bij  $>100 \mu\text{T}$
- 2) Toename in frequentie van 'buds' (= gen amplificatie) bij  $>50 \mu\text{T}$
- 3) Verminderd risico voor genetische schade bij 5 en 10  $\mu\text{T}$  (?)

## SCENIHR 2015

"The previous SCENIHR Opinion indicated a possible increase in Alzheimer's disease arising from exposure to ELF, stressing the need for further epidemiological and laboratory investigations".

### What has been achieved since then?


"Although the new studies in some cases have methodological weaknesses, they do not provide support for the previous conclusion that ELF MF exposure increases the risk for Alzheimer's disease".

+

Macedo et al. (2017) Is Sleep Disruption a Risk Factor for Alzheimer's Disease?  
J Alzheimers Dis. 2017;58(4):993-1002. doi: 10.3233/JAD-161287.


*Mechanisms triggered by sleep disruption may be involved in AD development, such as brain hypoxia, oxidative stress, circadian activity rhythms disturbances, overexpression of orexins, and blood-brain barrier impairment.*

**Verminderd risico voor genetische schade bij 5 - en 10 µT (?)**



Cuppen et al., (2007) Environmentalist, DOI 10.1007/s10669-007-9055-2

**Intermediaire frequenties: 7,5 kHz magnetisch veld**




- ⇒ Lage blootstellingen (aan LF-EMVen en andere omgevingsfactoren) stimuleren de immuun respons en DNA herstel
- ⇒ Stimulatie is effectiever in **geïnfecteerde weefsels/gestresseerde cellen** (ook niet getoonde gegevens); dus in geval van ziekte of onevenwicht.

EMV-blootstelling heeft minder effect wanneer de cellen gezond zijn!


⇒ HYPOTHESE:

EMVen veroorzaken een zwakke 'stress situatie' in cellen waardoor hun immuun systeem en andere 'alarm' systemen (vb. DNA herstel) 'voortijdig' activeren. Zo zullen zij bv. sneller dan normaal in staat zijn externe dreigingen (pathogenen e.d.) het hoofd te bieden. Pathogenen hebben op die manier minder kans om schadelijk te zijn.





Weinig pathogenen in het lichaam → verdedigingsmechanismen zijn (nog) niet geactiveerd




Invasie van  
pathogenen ↓  
**ALARM**

## ⇒ VERDEDIGING



## Wat doen ELF-MVen?





## MAAR: wat gebeurt er na langdurige (chronische) blootstelling aan ELF-MVen?

Er zijn beperkte aanwijzingen dat langdurige blootstellingen aanvankelijk leiden tot stimulatie van het immuun systeem maar dat dit nadien afneemt (uitputting?). Andere beperkte gegevens spreken dit dan weer tegen.

**Dit is tot op heden nooit voldoende onderzocht!!**



## BESLUIT

- Relatie tussen ELF-Mven en leukemie bij kinderen 'houdt voorlopig stand' maar er zijn andere, en wellicht belangrijkere oorzaken voor leukemie bij kinderen.
- Aanwijzingen voor een rol van ELF-MVen in het ontstaan van neurologische aandoeningen zoals de ziekte van Alzheimer zijn vooralsnog niet overtuigend maar volledig uitsluiten is (nog) niet mogelijk.
- ELF-MVen kunnen (net als andere stressoren zoals RF-straling maar ook andere fysische en chemische agentia) op korte termijn een milde (ongevaarlijke) 'stress-reactie' oproepen in cellen/organismen maar implicaties op lange termijn zijn vooralsnog onbekend.



DANK U